Quintrio
Home

Stock overview

YD Bio Limited Ordinary Shares

YDES

YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.

Last trade $4.69
Day change -$0.145 (-3.00%)
Day range $4.64 – $5.09
Volume 30,865
Market cap $342M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for YDES.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for YDES.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs

YD Bio and its affiliate EG BioMed have partnered with digital health provider JoiiUp to integrate an AI-driven cancer risk assessment tool into JoiiUp's JoiiSports app. The assessment, validated using over 1,200 clinical records from Taipei Medical University hospitals, analyzes demographic data and lifestyle factors across ten cancer types without requiring invasive testing. The tool will initially target corporate wellness programs through JoiiUp's network of 400+ companies, with planned expansion to healthcare institutions.

GlobeNewswire Inc.

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

YD Bio (Nasdaq: YDES), a biotechnology company focused on DNA methylation-based cancer detection and ophthalmologic innovations, announced H1 2026 results showing 315% revenue growth to $846.5 million and net income of $6.7 million. The profitability was primarily driven by a $9.8 million non-cash gain from warrant liability fair value changes. Excluding this adjustment, the company reported an operational net loss of $3.1 million. Revenue growth was fueled by large orders including a $327 million Fetroja order, though gross margins were pressured by lower-margin sales. The company is expanding its laboratory network, advancing exosome manufacturing, and pursuing strategic acquisitions while managing cash burn.

GlobeNewswire Inc.

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio announced the publication of a peer-reviewed article in Nutrients journal co-authored with physicians from Taiwan's Chronic Disease Healthcare Association and Future Health Institute. The article explores how omega-3, vitamin D3, and vitamin K2 affect cardiovascular, neurological, and skeletal health. This publication expands YD Bio's physician-partnership initiative beyond product development into peer-reviewed research.

GlobeNewswire Inc.

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

YD Bio announced that its affiliate EG BioMed US obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified laboratory's authorized operating footprint to 46 U.S. states plus Washington D.C. and Guam. The expansion supports the company's DNA methylation-based early cancer detection operations and broadens patient access to blood-based testing services for various cancers.

GlobeNewswire Inc.

YD Bio Limited Reports Full Year 2025 Financial Results

YD Bio (Nasdaq: YDES) announced full-year 2025 financial results showing 17% net revenue increase to $596.8 million, driven by pharmaceutical sales growth and new product launches. However, the company reported a net loss of $8.3 million compared to $1.4 million in 2024, primarily due to a $3.2 million change in warrant liabilities and increased operating expenses from business expansion. The company ended 2025 with $6.0 million in cash and outlined 2026 strategic priorities including FDA submissions for its Limbal Stem Cell platform and pancreatic cancer detection program, along with planned M&A activities.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.